Extracellular matrix remodeling following myocardial injury

Annals of Medicine

Volumn 35, Issue 5, 2003, Pages 316-326

  Lindsey, Merry L ^a   Mann, Douglas L ^b   Entman, Mark L ^b   Spinale, Francis G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Extracellular matrix; Matrix metalloproteinases; MMP inhibitor; Myocardial infarction

Indexed keywords

COLLAGEN; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

CELL DEATH; CELL FUNCTION; CELL STRUCTURE; CORONARY ARTERY BLOOD FLOW; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROSIS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HEART VENTRICLE REMODELING; INFLAMMATION; MUSCLE DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

CORONARY VESSELS; DILATATION, PATHOLOGIC; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HEART VENTRICLES; HUMANS; INTEGRINS; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 0041887170     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310001285     Document Type: Review

References (118)

1. Mann DL, Spinale FG. Activation of Matrix Metalloproteinases in the Failing Human Heart. Circulation 1998; 98: 1699-702.
2. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med 1998; 76: 253-65.
3. Weber KT. Extracellular Matrix Remodeling in Heart Failure. Circulation 1997; 96: 4065-82.
4. Weber KT, Sun Y, Tyagi SC, Cleutjens JPM. Collagen Network of the Myocardium: Function, Structural Remodeling and Regulatory Mechanisms. J Mol Cell Cardiol 1994; 26: 279-92.
5. Boudreau N, Bissell MJ. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr Opin Cell Biol 1998; 10: 640-6.
6. Swynghedauw B. Molecular Mechanisms of Myocardial Remodeling. Physiol Rev 1999; 79: 215-62.
7. Ross RS, Borg TK. Integrins and the Myocardium. Circ Res 2001; 88: 1112-9.
8. Spinale FG. Matrix Metalloproteinases: Regulation and Dysregulation in the Failing Heart. Circ Res 2002; 90: 520-30.
9. Scott-Burden T. Extracellular Matrix: The Cellular Environment. News Physiol Sci 1994; 9: 110-5.
10. Kanekar S, Hirozanne T, Terracio L, Borg TK. Cardiac Fibroblasts: Form and Function. Cardiovasc Pathol 1998; 7: 127-33.
11. Sheetz MP, Felsenfeld DP, Galbraith CG. Cell migration: regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol 1998; 8: 51-4.
12. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47: 23-37.
13. Humphries MJ, Newham P. The structure of cell-adhesion molecules. Trends Cell Biol 1998; 8: 78-83.
14. Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr Opin Chem Biol 2002; 6: 534-41.
15. Boudreau NJ, Jones PL. Extracellular matrix and integrin signalling: the shape of things to come. Biochem J 1999; 339: 481-8.
16. Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling. Hypertension 1998; 31: 176-80.
17. Keller RS, Shai S-Y, Babbitt CJ, Pham CG, Solaro RJ, Valencik ML, et al. Disruption of Integrin Function in the Murine Myocardium Leads to Perinatal Lethality, Fibrosis, and Abnormal Cardiac Performance. Am J Pathol 2001; 158: 1079-90.
18. Luscinskas FW, Lawler J. Integrins as dynamic regulators of vascular function. FASEB J 1994; 8: 929-38.
19. Tian B, Lessan K, Kahm J, Kleidon J, Henke C. beta 1 Integrin Regulates Fibroblast Viability during Collagen Matrix Contraction through a Phosphatidylinositol 3-Kinase/Akt/Protein Kinase B Signaling Pathway. J Biol Chem 2002; 277: 24667-75.
20. Damsky CH, Ilic D. Integrin signaling: it's where the action is. Curr Opin Cell Biol 2002; 14: 594-602.
21. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 2000; 46: 257-63.
22. Burgess ML, McCrea JC, Hedrick HL. Age-associated changes in cardiac matrix and integrins. Mech Ageing Dev 2001; 122: 1739-56.
23. Shai S-Y, Harpf AE, Babbitt CJ, Jordan MC, Fishbein MC, Chen J, et al. Cardiac Myocyte-Specific Excision of the {beta}1 Integrin Gene Results in Myocardial Fibrosis and Cardiac Failure. Circ Res 2002; 90: 458-64.
24. Danen EH, Lafrenie RM, Miyamoto S, Yamada KM. Integrin signaling: cytoskeletal complexes, MAP kinase activation, and regulation of gene expression. Cell Adhes Commun 1998; 6: 217-24.
25. Giancotti FG. Integrin signaling: specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 1997; 9: 691-700.
26. Schlaepfer DD, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol 1998; 8: 151-8.
27. Van Wart HE, Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87(Biochemistry)5578-82.
28. Tyagi SC, Matsubara L, Weber KT. Direct Extraction and Estimation of Collagenase(s) Activity by Zymography in Microquantities of Rat Myocardium and Uterus. Clin Biochem 1993; 26: 191-8.
29. 2-Macro-globulin with Matrix Meralloproteinases and Its Use for Identification of Their Active Forms. Ann NY Acad Sci 1994; 732: 294-302.
30. 2-Macroglobulin. Arch Biochem Biophys 1997; 347: 62-8.
31. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115: 3719-27.
32. Brew K, Dinakarpandian D, Nagase H. Tissue inbibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-83.
33. Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokha R, Schultz GA, et al. Murine tissue inhibitor of metalloproteinase-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997; 401: 213-7.
34. Liu YE, Wang M, Greene J, Su J, Ullrich S, Li H, et al. Preparation and Characterization of Recombinant Tissue inhibitor of Metalloproteinase 4 (TIMP-4). J Biol Chem 1997; 272: 20479-83.
35. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of ProMMP-1 and ProMMP-3 Activation by Tissue Factor Pathyway Inhibitor-2/Matrix-Associated Serine Protease Inhibitor. Biochem Biophys Res Commun 1999; 255: 94-8.
36. Stroud JD, Baicu CF, Barnes MA, Spinale FG, Zile MR. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol 2002; 282: H2324-35.
37. Pei D, Weiss SJ. Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity. J Biol Chem 1996; 271: 9135-40.
38. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, et al. TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase immobilized on Agarose Beads. J Biol Chem 1998; 273: 16098-103.
39. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Nagase H. Plasma Membrane-bound Tissue Inhibitor of Metalloproteinases (TIMP)-2 Specifically Inhibits Matrix Metalloproteinase 2 (Gelatinase A) Activated on the Cell Surface. J Biol Chem 1998; 273: 24360-7.
40. Cowell S, Knquper V, Stewart ML, D'Ortho M-P, Stanton H, Hembry RM, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 1998; 331: 453-8.
41. Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The Propeptide Domain of Membrane Type 1 Matrix Metalloproteinase Is Required for Binding of Tissue Inhibitor of Metalloproteinases and for Activation of Progelatinase A. J Biol Chem 1998; 273: 34745-52.
42. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, et al. The TIMP2 Membrane Type 1 Metalloproteinase "Receptor" Regulates the Concentration and Efficient Activation of Progelatinase A. J Biol Chem 1998; 273: 871-80.
43. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased Expression of Matrix Metalloproteinases and Marix Degrading Activity in Vulnerable Regions of Human Atherosclerotic Plaques. J Clin Invest 1994; 94: 2493-503.
44. Galis ZS, Khatri JJ. Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: The Good, the Bad, and the Ugly. Circ Res 2002; 90: 251-62.
45. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000; 105: 1641-9.
46. Carmeliet P. Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest 2000; 105: 1519-20.
47. Silence J, Collen D, Lijnen HR. Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene. Circ Res 2002; 90: 897-903.
48. Nagatomo Y, Carabello BA, Coker ML, McDermott PJ, Nemoto S, Hamawaki M, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000; 278: H151-61.
49. Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume Overload. Circulation 2002; 105: 1983-8.
50. Cox MJ, Sood HS, Hunt MJ, Chandler D, Henegar JR, Aru GM, et al. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2002; 282: H1197-205.
51. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000; 106: 857-66.
52. Lindsey M, Lee RT. MMP Inhibition as a Potential Therapeutic Strategy for CHF. Drug News Perspect 2000; 13: 350-4.
53. Li YY, Feldman AM. Matrix Metalloproteinases in the Progression of Heart Failure: Potential Therapeutic Implications. Drugs 2001; 61: 1239-52.
54. Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, et al. Targeted Disruption of the Matrix Metalloproteinase-9 Gene Impairs Smooth Muscle Cell Migration and Geometrical Arterial Remodeling. Circ Res 2002; 91: 852-9.
55. Clair MJ, Krombach RS, Coker ML, Heslin TL, Kribbs SB, de Gasparo M, et al. Angiotensin AT1 receptor inhibition in pacing induced heart failure: effects on left ventricular myocardial collagen content and composition. J Mol Cell Cardiol 1998; 30: 2355-64.
56. Spinale FG, Coker ML, Kromback SR, Mukherjee R, Hallak H, Houck WV, et al. Matrix Metalloproteinase Inhibition During the Development of Congestive Heart Failure. Circ Res 1999; 85: 364-76.
57. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev Cancer 2002; 2: 163-76.
58. Stetler-Stevenson WG. Matrix metalloproteinases in anglo-genesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
59. Pepper MS. Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
60. Cornelius LA, Nehring LC, Harding E, Bolanowshi M, Welgus HG, Kobayashi DK, et al. Matrix metalloproteinases generate angiostatin: effects of neovascularization. J Immunol 1998; 161: 6845-52.
61. Falcone DJ, Khan KMF, Layne T, Fernandes L. Macrophage Formation of Angiostatin during Inflammation. A byproduct of the activation of plasminogen. J Biol Chem 1998; 273: 31480-5.
62. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an Angiostatin-like Fragment from Plasminogen by Stromelysin-1 (MMP-3). Biochemistry 1998; 37: 4699-702.
63. Patterson BC, Sang QXA. Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9). J Biol Chem 1997; 272: 28823-5.
64. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 8: 171-7.
65. Birkedal-Hansen H, Cobb CM, Taylor RE, Fullmer HM. Synthesis and Release of Procollagenase by Cultured Fibroblasts. J Biol Chem 1976; 251: 3162-8.
66. Wang F, Trial J, Diwan A, Gao F, Birdsall H, Entman M, et al. Regulation of cardiac fibroblast cellular function by leukemia inhibitory factor. J Mol Cell Cardiol 2002; 34: 1309.
67. Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 Modulates Type I Collagen and Matrix Metalloproteinase Gene Expression in Cultured Human Skin Fibroblasts. J Clin Invest 1994; 94: 2489-92.
68. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435: 29-34.
69. Giambernardi TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol 1998; 16: 483-96.
70. Overall CM, Wrana JL, Sodek J. Independent Regulation of Collagenase, 72-kDa Progelatinase, and Metalloendoproteinase Inhibitor Expression in Human Fibroblasts by Transforming Growth Factor-b. J Biol Chem 1989; 264: 1860-9.
71. Edwards DR, Leco KJ, Beaudry PP, Atadia PW, Veillette C, Riabowol KT. Differential Effects of Transforming Growth Factor-b1 On the Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Young and Old Human Fibroblasts. Exp Gerontol 1996; 31: 207-23.
72. Ravanti L, Toriseva M, Penttinen R, Crombleholme T, Foschi M, Han J, et al. Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase. FASEB J 2001; 15: 1098-100.
73. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, et al. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 1996; 271: 28485-91.
74. Leicht M, Briest W, Holzl A, Zimmer H-G. Serum depletion induces cell loss of rat cardiac fibroblasts and increased expression of extracellular matrix proteins in surviving cells. Cardiovasc Res 2001; 52: 429-37.
75. Heggtveit HA. Morphological Alterations in the Ischaemic Heart. Cardiology 1971/72; 56: 284-90.
76. Kim CB, Braunwald E. Potential Benefits of Late Reperfusion of Infarcted Myocardium: The Open Artery Hypothesis. Circulation 1993; 88: 2426-36.
77. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
78. Kapadia S, Dibbs Z, Kurrelmeyer KM, Kalra D, Seta Y, Wang F, et al. The role of cyrokines in the falling human heart. In: Crawford M, ed. Cardiol Clin Philadelphia: WB Saunders; 1998: 645-56.
79. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997; 79: 1128-31.
80. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 391-8.
81. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant 1998; 17: 356-62.
82. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
83. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
84. Ferrari R. Interleukin-6: a neurohumoral predictor of prognosis in patients with heart failure: light and shadow. Eur Heart J 2002; 23: 9-10.
85. Sivasubramanian N, Coker ML, Kurrelmeyer KM MacLellan WR, DeMayo FJ, Spinale FG, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001; 104: 826-31.
86. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-7.
87. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002; 8: 390-8.
88. Bradham WS, Gunasinghe H, Holder JR, Multani M, Killip D, Anderson M, et al. Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2002; 40: 2165-73.
89. Jensen LR, Horslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE, et al. Serum Aminoterminal Type III Procollagen Peptide Reflects Repair After Acute Myocardial Infarction. Circulation 1990; 81: 52-7.
90. Poulsen SH, Host NB, Jensen SE, Egstrup K. Relationship Between Serum Amino-Terminal Propeptide of Type III Procollagen and Changes of Left Ventricular Function After Acute Myocardial Infarction. Circulation 2000; 101: 1527-32.
91. Cleutjens JPM, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of Collagen Degradation in the Rat Myocardium after Infarction. J Mol Cell Cardiol 1995; 27: 1281-92.
92. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000; 46: 307-15.
93. Rohde LE, Aikawa M, Cheng GC, Sukhova G, Solomon SD, Libby P, et al. Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimenral myocardial infarction. J Am Coll Cardiol 1999; 33: 835-42.
94. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, et al. Matrix-Dependent Mechanism of Neutrophil-Mediated Release and Activation of Matrix Metalloproteinase 9 in Myocardial Ischemia/Reperfusion. Circulation 2001; 103: 2181-7.
95. Baghelai K, Marktanner R, Dattilo JB, Dattilo MPM, Jakoi E, Yager DR, et al. Decreased Expression of Tissue Inhibitor of Metalloproteinase 1 in Stunned Myocardium. J Surg Res 1998; 77: 35-9.
96. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 2001; 68: 799-814.
97. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, et al. Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 2002; 54: 549-58.
98. Mann DL. Basic Mechanisms of Disease Progression in the Failing Heart: The Role of Excessive Adrenergic Drive. Prog Cardiovasc Dis 1998; 41(1 Suppl 1)1-8.
99. Kurrelmeyer K, Kalra D, Bozkurt B, Wang F, Dibbs Z, Seta Y, et al. Cardiac Remodeling as a Consequence and Cause of Progressive Heart Failure. Clin Cardiol 1998; 21(Suppl I)I14-9.
100. Janicki JS, Brower GL, Henegar JR, Wang L. Ventricular remodeling in heart failure: the role of myocardial collagen. Adv Exp Med Biol 1995; 382: 239-45.
101. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44-51.
102. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55-62.
103. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5: 1135-42.
104. Creemers EEJM, Davis JN, Parkhurst AM, Leenders P, Dowdy KB, Hapke E, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003; 284: H364-71.
105. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, et al. Selective Matrix Metalloproteinase Inhibition Reduces Left Ventricular Remodeling but Does Not Inhibit Angiogenesis After Myocardial Infarction. Circulation 2002; 105: 753-8.
106. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, et al. Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition. Circulation 2003; 107: 618-25.
107. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387-92.
108. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995; 64: 1312-8.
109. Diekmann O, Tschesche H. Degradation of kinins, angiotensins and substance P by polymorphonuclear matrix metalloproteinases MMP 8 and MMP 9. Braz J Med Biol Res 1994; 27: 1865-76.
110. Fowlkes JL, Thrailkill KM, Serra DM, Nagase H. Insulin-like growth factor binding protein (IGFBP) substrate zymography. A new tool to identify and characterize IGFBP-degrading proteinases. Endocrine 1997; 7: 33-6.
111. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994; 269: 25742-6.
112. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, Diaz LA, et al. The Serpin a1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 In Vivo. Cell 2000; 102: 647-55.
113. Lijnen HR, Arza B, Van Hoef B, Collen D, Declerck PJ. Inactivation of Plasminogen Activator-1 by Specific Proteolysis with Stromelysin-1 (MMP-3). J Biol Chem 2000; 275: 37645-50.
114. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO- alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-81.
115. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-7.
116. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 2001; 276: 20572-8.
117. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996; 155: 13-21.
118. Herzog E, Gu A, Kohmoto T, Burkhoff D, Hochman JS. Early Activation of Metalloproteinases after Experimental Myocardial Infarction Occurs in Infarct and Non-Infarct Zones. Cardiovasc Pathol 1998; 7: 307-12.